Impact of reduced vancomycin susceptibility on the therapeutic outcome of MRSA bloodstream infections

Table 1 Clinical summary of patients eligible for this study

Pt no.	Sex	Age	Underlying disease	ASA^a	Hospitalization days	VCM Treatment days^b	Shock	Infection source	MRSA carrier^e
1	M	58	Extraheptic bile duct carcinoma, post operation liver failure	IV	86	9	yes	SSI^c	no
2	F	28	Pneumonia, alchoholic hepatitis	III	92	5	yes (DIC)	CVC	no
3	F	25	Multiple sclerosis, steroids therapy	III	67	20	no	transfusion	no
4	M	66	Liver cirrhosis, renal dialysis, brain stroke	IV	129	19	yes (DIC)	unknown	no
5	M	70	Renal dialysis, brain stroke, surgery in admission	IV	85	12	yes	SSI	no
6	F	91	Diabetes, chronic heart failure	IV	252	16	no	CVC^d	yes
7	M	22	Germ cell tumour, chemotherapy	III	301	9	no	CVC	yes
8	M	63	Diabetes, brain stroke, aspiration	IV	260	11	yes	unknown	no
9	F	57	Diabetes, SLE, surgery in admission	IV	137	23	yes	pressure sore	yes
10	M	38	Lung cancer, chemotherapy, metastasis	IV	105	19	no	pressure sore	no
11	F	73	Brain stroke, aspiration, surgery in admission	IV	43	15	no	CVC	yes
12	F	3	B cell lymphoproliferative disorder, steroids	III	50	8	no	CVC	yes
13	M	77	Diabetes, chronic renal failure, aspiration	IV	281	10	no	CVC	no
14	M	59	Renal cancer, metastasis to bone, lung	IV	111	7	no	CVC	no
15	M	79	Lung cancer, chemotherapy	III	430	17	no	cellulitis	no
16	M	57	Non-Hodgkin's lymphoma, chemotherapy	IV	21	14	no	unknown	no
17	F	67	Liver cancer, liver cirrhosis, hypertension	III	69	9	no	port	no
18	F	22	Pulmonary embolism, bone tumour transplantation	III	86	19	no	transplantation	no
19	M	72	Encephalopathy, apical OMI, aspiration pneumonia	IV	59	10	no	CVC	no
20	M	62	Heart failure, acute myocardial infarct	IV	54	24	yes	CVC	no

a) ASA (American Association of Anaesthetists) scoring to assess patients' underlying conditions: I, a completely healthy patient; II, a patient with mild systemic disease; III, a patient with severe systemic disease that is not incapacitating; IV, a patient with incapacitating disease that is a constant threat to life; V, a moribundpatient who is not expected to live 24 hours with or without surgery.
b) Duration of vancomycin treatment
c) SSI, surgical site infection
d) CVC, central venous catheter
e) MRSA nasal carrier during hospital admission

ISSN: 1476-0711